Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.16 USD
−67.67 M USD
0.00 USD
41.36 M
About Cabaletta Bio, Inc.
Sector
Industry
CEO
Steven Nichtberger
Website
Headquarters
Philadelphia
Founded
2017
FIGI
BBG00MJ3BKW2
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CABA is 1.87 USD — it has decreased by −17.26% in the past 24 hours. Watch Cabaletta Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cabaletta Bio, Inc. stocks are traded under the ticker CABA.
CABA stock has fallen by −54.05% compared to the previous week, the month change is a −58.35% fall, over the last year Cabaletta Bio, Inc. has showed a −89.28% decrease.
We've gathered analysts' opinions on Cabaletta Bio, Inc. future price: according to them, CABA price has a max estimate of 35.00 USD and a min estimate of 10.00 USD. Watch CABA chart and read a more detailed Cabaletta Bio, Inc. stock forecast: see what analysts think of Cabaletta Bio, Inc. and suggest that you do with its stocks.
CABA reached its all-time high on Feb 8, 2024 with the price of 26.35 USD, and its all-time low was 0.59 USD and was reached on Sep 23, 2022. View more price dynamics on CABA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CABA stock is 11.05% volatile and has beta coefficient of 4.12. Track Cabaletta Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cabaletta Bio, Inc. there?
Today Cabaletta Bio, Inc. has the market capitalization of 91.40 M, it has decreased by −38.28% over the last week.
Yes, you can track Cabaletta Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Cabaletta Bio, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
CABA earnings for the last quarter are −0.62 USD per share, whereas the estimation was −0.60 USD resulting in a −3.99% surprise. The estimated earnings for the next quarter are −0.64 USD per share. See more details about Cabaletta Bio, Inc. earnings.
Cabaletta Bio, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CABA net income for the last quarter is −30.63 M USD, while the quarter before that showed −27.60 M USD of net income which accounts for −10.97% change. Track more Cabaletta Bio, Inc. financial stats to get the full picture.
No, CABA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 103.00 employees. See our rating of the largest employees — is Cabaletta Bio, Inc. on this list?
Like other stocks, CABA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cabaletta Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cabaletta Bio, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cabaletta Bio, Inc. stock shows the sell signal. See more of Cabaletta Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.